New drug duo tested for Tough-to-Treat breast cancer
NCT ID NCT06612203
Summary
This study is testing whether adding a new oral drug, Debio 0123, to an existing cancer drug, sacituzumab govitecan, is safe and can help control advanced breast cancer. It is for people whose cancer has worsened after one or two prior treatments. The goal is to see if this combination can shrink tumors or stop them from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, United Kingdom
-
Beatson West of Scotland Cancer Center
Glasgow, United Kingdom
-
Hospital Arnau de Vilanova de Valencia
Valencia, Spain
-
Hospital Beata María Ana
Madrid, Spain
-
Hospital Universitari Dexeus
Barcelona, Spain
-
Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Conditions
Explore the condition pages connected to this study.